Back to Sectors

SINT

Sintx Technologies, Inc.
3 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 70% | 5/15/2026 | earnings missBULLISH | 40% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 60% | 5/15/2026 | divestitureBEARISH | 70% | 5/15/2026 | earnings missBULLISH | 40% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 60% | 5/15/2026 | divestitureBEARISH | 90% | 5/27/2026 | regulatory actionNEUTRAL | 60% | 5/27/2026 | capital raiseBEARISH | 80% | 5/27/2026 | dilution riskMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 27

Nasdaq issued a delisting notice due to failure to meet minimum stockholders' equity requirements.

regulatory action
90%
neutralMay 27

Company is actively pursuing equity financing to regain listing compliance.

capital raise
60%
bearishMay 27

Urgent need for capital to avoid delisting increases the likelihood of highly dilutive equity issuance.

dilution risk
80%
bearishMay 15

Net loss widened to $2.82 million compared to $2.29 million in the prior year period.

earnings miss
70%
bullishMay 15

Gross profit increased by 17% due to a shift toward higher-margin product sales.

margin expansion
40%
neutralMay 15

Utilization of ATM program to raise $0.7 million to support ongoing operations.

capital raise
50%
bullishMay 15

Sale of TA&T subsidiary to streamline operations and reduce liabilities.

divestiture
60%
bearishMay 15

Net loss widened to $2.82 million compared to $2.29 million in the prior year period.

earnings miss
70%
bullishMay 15

Gross profit increased by 17% due to a shift toward higher-margin product sales.

margin expansion
40%
neutralMay 15

Utilization of ATM program to raise $0.7 million to support ongoing operations.

capital raise
50%
bullishMay 15

Sale of TA&T subsidiary to streamline operations and reduce liabilities.

divestiture
60%

Filing History

8-KMay 27, 2026

SINTX Technologies is currently navigating a critical juncture where its ability to remain a public entity depends on a rapid infusion of capital. While the company intends to submit a compliance plan to Nasdaq by July 6, 2026, the outcome remains uncertain given the substantial gap in required stockholders' equity. The market now watches to see if the company can leverage its strategic discussions into a viable financing deal that stabilizes the balance sheet without excessively eroding existing shareholder value.

10-QMay 15, 2026

The Q1 2026 filing presents a company at a critical crossroads, balancing a promising product pipeline against a deteriorating balance sheet. On one hand, the FDA clearance and initial revenue from the SiNAPTIC system prove the technical viability of SINTX's silicon nitride technology. On the other hand, the explicit 'substantial doubt' regarding the company's ability to continue as a going concern for the next 12 months underscores the urgency of their commercial execution. Investors are essentially betting on whether the speed of the commercial ramp can outpace the rate of cash depletion. While the divestiture of non-core assets and the shift toward higher-margin products are positive strategic moves, they have not yet translated into operational sustainability. The overall impact of the filing is a high-risk, high-reward scenario where the technical moat is evident, but the financial runway is dangerously short.